Table IV.
Odds ratios and 95% CI for BRCA1 promoter methylation and breast cancer subtype.
| Heterogeneity test | |||||
|---|---|---|---|---|---|
| Factors | Pooled OR (95% CI) | P-valuea | χ2 | P-value | I2 (%) |
| ER negative | |||||
| Asian | 1.329 (1.084–1.630) | 0.006 | 9.41 | 0.052 | 57.5 |
| European | 1.040 (0.736–1.471) | 0.824 | 0.14 | 0.704 | 0.0 |
| Overall | 1.247 (1.045–1.487) | 0.014 | 10.83 | 0.094 | 44.6 |
| PR negative | |||||
| Asian | 1.459 (1.195–1.782) | <0.001 | 15.62 | 0.004 | 74.4 |
| European | 1.010 (0.740–1.379) | 0.948 | 0.28 | 0.599 | 0.0 |
| Overall | 1.311 (1.108–1.550) | 0.002 | 19.30 | 0.004 | 68.9 |
| HER2 negative | |||||
| Asian | 2.834 (2.277–3.528) | <0.001 | 2.98 | 0.394 | 0.0 |
| European | 2.881 (2.322–3.574) | <0.001 | 3.65 | 0.456 | 0.0 |
| Triple-negative | |||||
| Asian | 1.557 (1.210–2.002) | 0.001 | 2.81 | 0.422 | 0.0 |
| European | 1.494 (1.178–1.896) | 0.001 | 3.61 | 0.461 | 0.0 |
a
P-value for the association from the meta-analysis. CI, confidence interval; OR, odds ratio; ER, estrogen receptor; BRCA1, breast cancer susceptibility gene 1; HER2, human epidermal growth factor receptor 2.